The existence of HCC may be related to long-term inflammation due to CHB. Therefore, more in-depth studies should be conducted with more samples from a broader population to further elucidate the molecular mechanism by which FOXP3 affects the development of HCC. Acknowledgments We are RG7112 mouse grateful to all the subjects who participated in this study. We acknowledge the kind provision of technical knowledge by Bio Miao Biological Technology Co., Ltd (Beijing, China). This work was supported by the National Y-27632 Natural Science Foundation of China (No. 91029741 and No. 81001072), the National Key Sci-Tech
Special Project of China (No. 2012ZX10002011-006), Beijing Natural science foundation (No. 5112032) Magnitude science and technology projects of Henan province (No.122102310056 and No.132102310182). Electronic supplementary material Additional file 1: Table S1:
The analysis of FOXP3 SNPs genotypes in all donors. The 2 × 2 tables were used for two comparisons of genotypes respectively in HCC patients or CHB patients versus healthy donors, to get accurate individual P-values. (PDF 83 KB) References 1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61:69–90.PubMedCrossRef 2. Schreiber RD, Old LJ, Smyth MJ: Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 2011, 331:1565–1570.PubMedCrossRef 3. Kullberg MC, Jankovic D, Gorelick PL, Caspar P, Letterio JJ, Cheever AW, Sher A: Bacteria-triggered GSK3235025 order CD4(+) T regulatory PtdIns(3,4)P2 cells suppress Helicobacter hepaticus-induced colitis. J Exp Med 2002, 196:505–515.PubMedCrossRef 4. Tsunemi S, Iwasaki T, Imado
T, Higasa S, Kakishita E, Shirasaka T, Sano H: Relationship of CD4 + CD25+ regulatory T cells to immune status in HIV-infected patients. AIDS 2005, 19:879–886.PubMedCrossRef 5. Aandahl EM, Michaelsson J, Moretto WJ, Hecht FM, Nixon DF: Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol 2004, 78:2454–2459.PubMedCrossRef 6. Xu D, Fu J, Jin L, Zhang H, Zhou C, Zou Z, Zhao JM, Zhang B, Shi M, Ding X, et al.: Circulating and liver resident CD4 + CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 2006, 177:739–747.PubMed 7. Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057–1061.PubMedCrossRef 8. Fontenot JD, Gavin MA, Rudensky AY: Foxp3 programs the development and function of CD4 + CD25+ regulatory T cells. Nat Immunol 2003, 4:330–336.PubMedCrossRef 9. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, et al.: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10:942–949.